Company Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke.
Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases.
In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Dietrich John Pauls MBA |
Contact Details
Address: 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota 55305 United States | |
| Phone | (763) 496-5454 |
| Website | diamedica.com |
Stock Details
| Ticker Symbol | DMAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401040 |
| CUSIP Number | 25253X207 |
| ISIN Number | CA25253X2077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dietrich John Pauls MBA | President, Chief Executive Officer and Director |
| Scott Kellen C.P.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Kirsten L. Gruis M.D., M.S. | Independent Consultant |
| Julie VanOrsdel Daves CCRP | Senior Vice President of Clinical Development Operations |
| Dr. Ambarish Shah Ph.D. | Chief Technology Officer |
| Dominic R. Cundari | Chief Commercial Officer |
| David J. Wambeke | Chief Business Officer |
| Dr. Lorianne K. Masuoka M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 8-K | Current Report |
| Apr 9, 2024 | EFFECT | Notice of Effectiveness |
| Apr 4, 2024 | ARS | Filing |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 19, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |